Boulder’s Biodesix closes on $8.8M to expand r&d, sales efforts

Boulder-based Biodesix Inc., a venture-backed molecular diagnostics firm, landed $8.8 million in a follow-on sale of Series D preferred shares, company officials announced Thursday.

Biodesix plans to use the money for product development and to bolster sales and marketing efforts related to VeriStrat, a product aimed at identifying the effectiveness of potential treatments for non-small cell lung cancer patients.

Separately, Biodesix announced it inked a collaboration agreement with Bruker Daltonics. The support agreement expands on an existing partnership that involves the use of Bruker’s mass spectrometry instruments with other products in development.

About Alicia Wallace

Alicia Wallace is the business reporter for the Boulder Daily Camera.
This entry was posted in Bioscience, Boulder. Bookmark the permalink.

Comments are closed.